Saturday 17 October 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22,375.6%, EPS grew 48.2% and free cash flow fell 9.01%, each against the same quarter a year earlier.
36.05
1.40
−3.74%
Follow SEPN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
15.25 | 14.89 | 26.85 | 37.84 | |
P/FCF ratio |
12.83 | 9.01 | 10.10 | 7.21 | |
P/Operating CF |
(68.01) | (41.96) | (82.33) | 4.94 | |
P/B ratio |
3.90 | 2.84 | 3.23 | 2.15 | |
Price to Tangible BV |
3.90 | 2.84 | 3.23 | 2.15 | |
EV/Sales |
11.49 | 10.08 | 18.34 | 16.32 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
10.72 | 6.75 | 7.65 | 3.45 | |
EV/FCF |
9.66 | 6.10 | 6.90 | 3.11 | |
Quick Ratio |
4.85 | 4.58 | 4.62 | 6.42 | |
Current Ratio |
4.99 | 4.71 | 4.73 | 6.53 | |
Net Debt/EBITDA |
22.69 | 26.97 | 25.03 | (157.33) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.20 | 0.14 | 0.09 | 0.06 | |
Operating CF/Net income |
1.70 | 2.97 | 1.40 | 20.65 | |
Capex/Depreciation |
0.00 | (1.98) | (0.16) | 31.14 | |
Research and Development Expense of Revenue |
131.35% | 111.36% | 132.10% | 112.88% | |
Selling, General and Administrative Expense of Revenue |
31.59% | 38.79% | 34.33% | 33.11% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
18.97% | 22.68% | 11.01% | 11.78% | |
Graham Net Nets |
0.14 | 0.16 | 0.16 | 0.33 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.61%) | (3.37%) | (3.98%) | (8.03%) | |
Free Cash Flow Yield |
7.80% | 11.10% | 9.90% | 13.87% | |
Revenue per Share |
0.59 | 0.59 | 0.54 | 0.48 | |
Operating CF per Share |
(0.49) | (0.57) | (0.34) | 3.81 | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.28 | |
Free Cash Flow per Share |
(0.49) | (0.59) | (0.34) | 4.09 | |
Cash per Share |
8.27 | 7.76 | 8.84 | 10.70 | |
Shareholders Equity per Share |
8.59 | 8.46 | 8.63 | 8.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.59 | 8.46 | 8.63 | 8.77 | |
Free Cash Flow |
(22.18) | (26.46) | (15.05) | 181.29 | |
Working Capital |
316.84 | 289.89 | 324.03 | 416.40 | |
Capital Expenditures |
0.00 | (0.83) | (0.06) | 12.49 | |
Net Current Asset Value |
216.14 | 176.83 | 196.70 | 273.76 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.00 | (0.58) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.16 | 5.55 | 5.26 | 4.43 | |
Average Payables |
5.26 | 5.91 | 6.74 | 4.93 | |
Average Assets |
490.98 | 501.85 | 526.37 | 390.47 | |
Average Common Equity |
382.14 | 389.36 | 400.99 | 150.66 |
Columns are period end dates